Leelamma George, MD
Internal Medicine · Colonial Heights, VANPI 1306886007
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.4% of the total across 109 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 26 manufacturers, the largest accounting for just 18.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $692 and has fallen 97.5% since, to $18 in 2025.
Across 109 payments — averaging $18.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$373
- AstraZeneca$239
- Astellas Pharma US Inc$222
- Novo Nordisk$147
- Johnson & Johnson$105
- AbbVie$104
- plus $873 from 20 others
What the payments were for
- Food & beverage$1,98796%
- Education$754%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 19 | $373 |
| AstraZeneca | 15 | $239 |
| Astellas Pharma US Inc | 9 | $222 |
| Novo Nordisk | 9 | $147 |
| Johnson & Johnson | 5 | $105 |
| AbbVie(2 entities) | 6 | $104 |
| Pfizer | 5 | $92 |
| Boehringer Ingelheim | 4 | $86 |
| Merck | 5 | $83 |
| Esperion Therapeutics, Inc. | 4 | $80 |
| Supernus Pharmaceuticals, Inc. | 2 | $63 |
| Novartis | 3 | $59 |
| Sanofi-aventis U.S. LLC | 2 | $41 |
| Amgen | 2 | $40 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $39 |
| Abbott | 2 | $36 |
| Ironwood Pharmaceuticals, Inc | 2 | $34 |
| Lilly USA, LLC | 2 | $33 |
| Nestle Healthcare Nutrition Inc. | 2 | $33 |
| Genentech USA, Inc. | 2 | $30 |
| Kowa Pharmaceuticals America, Inc. | 2 | $28 |
| Dexcom, Inc. | 1 | $22 |
| Ultragenyx Pharmaceutical Inc. | 1 | $21 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $19 |
| Exact Sciences | 1 | $18 |
| Bayer | 1 | $16 |
How this compares
$2,062 in reported general payments places this provider in the 85th percentile of 2,724 internal medicine providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 131 | $147,950 |
| TrulicityDulaglutide | 64 | $71,162 |
| OzempicSemaglutide | 52 | $61,386 |
| JanuviaSitagliptin Phosphate | 42 | $36,677 |
| JanumetSitagliptin Phos/Metformin Hcl | 39 | $34,927 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 41 | $33,473 |
| MounjaroTirzepatide | 30 | $31,727 |
| LinzessLinaclotide | 47 | $31,468 |
| FarxigaDapagliflozin Propanediol | 34 | $31,261 |
| EliquisApixaban | 25 | $24,453 |
| CreonLipase/Protease/Amylase | 28 | $23,676 |
| XareltoRivaroxaban | 22 | $14,228 |
| SymbicortBudesonide/Formoterol Fumarate | 23 | $7,033 |
| BelsomraSuvorexant | 11 | $6,545 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 51 | $5,567 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $86 | $147,950131 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $33 | $102,89094 claims |
| MerckJanuvia, Janumet, Belsomra | $83 | $78,14992 claims |
| Novo NordiskOzempic | $147 | $61,38652 claims |
| AbbVieLinzess, Creon | $104 | $55,14575 claims |
| AstraZenecaFarxiga, Symbicort | $239 | $38,29457 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $373 | $38,12153 claims |
| PfizerEliquis | $92 | $24,45325 claims |
| Johnson & JohnsonXarelto | $105 | $14,22822 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,724 internal medicine providers in Virginia.
Other internal medicine in Colonial Heights
- Kumar AbhishekMechanicsville$1M
- Amit MahajanFalls Church$1M
- Kevin DonohueFalls Church$655K
- Denise BrunerArlington$227K
- Anjali KaloreMidlothian$215K
- Scott GerrishVienna$207K
- Lawrence SchwartzRichmond$205K
- Wally SmithRichmond$177K
- Gautam GulatiMc Lean$136K
- Francesse BatailleDumfries$109K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.